State of Alaska Department of Revenue Lowers Stock Position in Encompass Health Co. (NYSE:EHC)

State of Alaska Department of Revenue cut its position in shares of Encompass Health Co. (NYSE:EHCGet Rating) by 2.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 13,851 shares of the company’s stock after selling 340 shares during the quarter. State of Alaska Department of Revenue’s holdings in Encompass Health were worth $626,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in EHC. Baupost Group LLC MA raised its position in Encompass Health by 318.9% during the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company’s stock worth $213,330,000 after acquiring an additional 2,283,900 shares during the period. Massachusetts Financial Services Co. MA raised its position in Encompass Health by 88.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,685,880 shares of the company’s stock worth $94,494,000 after acquiring an additional 792,813 shares during the period. Victory Capital Management Inc. raised its position in Encompass Health by 40.0% during the second quarter. Victory Capital Management Inc. now owns 2,146,910 shares of the company’s stock worth $120,335,000 after acquiring an additional 613,547 shares during the period. Davide Leone & Partners Investment Co Ltd. raised its position in Encompass Health by 350.1% during the second quarter. Davide Leone & Partners Investment Co Ltd. now owns 394,752 shares of the company’s stock worth $22,126,000 after acquiring an additional 307,047 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Encompass Health by 21.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,464,313 shares of the company’s stock worth $104,127,000 after acquiring an additional 254,385 shares during the period. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Price Performance

Encompass Health stock opened at $59.75 on Thursday. Encompass Health Co. has a 12-month low of $44.33 and a 12-month high of $74.61. The stock has a market cap of $5.96 billion, a P/E ratio of 21.97, a PEG ratio of 2.59 and a beta of 1.02. The company has a 50-day moving average price of $57.57 and a 200 day moving average price of $52.76. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 1.59.

Encompass Health (NYSE:EHCGet Rating) last released its quarterly earnings data on Wednesday, October 26th. The company reported $0.67 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.68 by ($0.01). Encompass Health had a return on equity of 15.59% and a net margin of 5.39%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.06 billion. Sell-side analysts anticipate that Encompass Health Co. will post 2.79 earnings per share for the current year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 17th. Investors of record on Tuesday, January 3rd will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 1.00%. The ex-dividend date is Friday, December 30th. Encompass Health’s payout ratio is currently 22.06%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EHC. TheStreet upgraded shares of Encompass Health from a “c+” rating to a “b-” rating in a research report on Wednesday, December 21st. StockNews.com began coverage on shares of Encompass Health in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Raymond James increased their target price on shares of Encompass Health from $65.00 to $72.00 and gave the company a “strong-buy” rating in a research report on Friday, October 28th. Credit Suisse Group reduced their target price on shares of Encompass Health from $63.00 to $62.00 and set an “outperform” rating for the company in a research report on Wednesday, September 21st. Finally, Stephens reduced their target price on shares of Encompass Health from $60.00 to $58.00 and set an “overweight” rating for the company in a research report on Friday, October 28th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $64.13.

Insiders Place Their Bets

In related news, Director Greg D. Carmichael bought 1,830 shares of the stock in a transaction on Monday, October 31st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the director now directly owns 10,546 shares in the company, valued at approximately $576,549.82. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is currently owned by insiders.

Encompass Health Company Profile

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Read More

Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHCGet Rating).

Institutional Ownership by Quarter for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.